Competing drugmaker Sanofi accused Mylan of offering illegal rebates that ensured its market dominance for epinephrine auto-injectors like EpiPen.
LabCorp is beginning a cost-cutting initiative in its contract research business after revenue and earnings slipped in the first quarter at its Covance Drug Development unit. The unit's performance dampened what ultimately turned out to be a positive quarter for the diagnostics giant.
The Cherokee Nation claims the companies should have prevented rather than profited from the opioid epidemic and the mass distribution of addictive pain pills.
The tentative deal to reauthorize the FDA's ability to collect user fees could be a boon to many healthcare companies by providing more certainty and efficiency in the product approval process, healthcare and legal experts said.
The Pennsylvania-based company has struggled to attract customers of its wearable drug injectors.
Even as the death toll rises, opioid addiction isn't treated with urgency like other chronic and deadly diseases. Health insurers make patients and families jump through too many hoops to get coverage for needed inpatient and outpatient care for addiction, including medication-assisted treatment.
Lawmakers must extend FDA's user fee authorization by the end of September to avoid significant agency layoffs and drug and device review delays.
Hospitals experiencing a shortage of generic sterile injectable drugs will likely see a spike in their mortality rates, according to a new study.
President Donald Trump is expected to nominate U.S. Rep. Tom Marino of Pennsylvania to lead the nation's efforts to curb drug addiction, according to news reports.
Michigan on Tuesday announced it launched its improved Michigan Automated Prescription System, which doctors and other controlled substance providers are encouraged to use to more accurately track prescription drugs in an effort to combat rising overdose deaths.
A bipartisan pair of congressmen on Thursday proposed a bill in the U.S. House of Representatives to try to prevent drugmakers from blocking generic and biosimilar competitors.
A top maker of brand-name and generic narcotic painkillers has agreed to pay the U.S. government $35 million to resolve a probe of its distribution of those drugs.